SCHEMBL4002163

SCHEMBL4002163

COC(=O)C1(C)CN(c2ccccc2)C(=O)N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 5/20 0.46
OPRL1 P41146 5/20 0.46
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
HSD17B10 Q99714 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 2/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
CYP3A4 P08684 2/20 0.39
CYP2C19 P33261 2/20 0.39
USP2 O75604 1/20 0.39
GAA P10253 2/20 0.39
MAPT P10636 2/20 0.39
G6PD P11413 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CASP3 P42574 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2058368 0.86 L3MBTL1 (0.42) OPRM1OPRL1MEN1KMT2AALDH1A1
SCHEMBL4002127 0.84 OPRM1 (0.41) OPRM1OPRL1MEN1KMT2AALDH1A1
SCHEMBL4001442 0.80 ALDH1A1 (0.45) OPRM1OPRL1MEN1KMT2AHSD17B10
SCHEMBL14989002 0.77 OPRM1 (0.44) OPRM1OPRL1MEN1KMT2AHSD17B10
SCHEMBL27913504 0.74 AR (0.51) OPRM1OPRL1MEN1KMT2AKDM4E
SCHEMBL4004869 0.72 AR (0.53)
SCHEMBL2058630 0.72 AR (0.41) OPRM1OPRL1MEN1KMT2APOLB
SCHEMBL14989006 0.71 ALDH1A1 (0.40) OPRM1OPRL1MEN1KMT2AALDH1A1
SCHEMBL22559975 0.71 GAA (0.43) OPRM1OPRL1MEN1KMT2AKDM4E
SCHEMBL30577920 0.71 HDAC8 (0.49) MEN1KMT2AHSD17B10CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791821-B1 NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2013-06-05 EP claimed
CN-101056862-B Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA NV 2013-03-13 CN claimed
US-7531565-B2 Imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA, N.V. (BE) 2009-05-12 US claimed
CN-101056862-A Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2007-10-17 CN claimed
EP-1791821-A2 NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-06 EP claimed
US-20060063819-A1 Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2006-03-23 US claimed
WO-2006031715-A2 NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2006-03-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063819-A1 Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) AR, NR5A1, NR5A2 OPRM1 135/4885OPRL1 390/4885MEN1 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.